Table 3. Skeletal phenotype of juvenile Bmp2^Flox/Flox; Prx1-Cre mice after intermittent PTH therapy.

Juvenile mice (two weeks-old) were given intermittent PTH_1-34 therapy (100 mg/kg, subcutaneous) for 14 days. Bone mass was analyzed in the femur by microcomputed tomography (microCT). Trabecular bone at the distal metaphysis and cortical bone at the mid-diaphysis of the femur are presented as group mean ± s.d. and statistically compared by 2-way ANOVA. BV/TV, bone volume fraction; Conn.D, connectivity density; SMI, structure model index; Tb.N, trabecular number; Tb.Th, trabecular thickness; Tb.Sp, Trabecular separation; Tt.Ar, total cross-sectional area; Ct.Ar, cortical bone area; Ct.Ar/Tt.Ar, cortical area fraction; Ct.Th, average cortical thickness; Imin, minimum moment of inertia; Ma.V, marrow volume. P^a ≤ 0.05 vs. WT. P^b ≤0.05 vs. Vehicle.

MicroCT femur, four wk	Bmp2Flox/Flox		Bmp2Flox/Flox; Prx1-Cre
Treatment	Vehicle	PTH	Vehicle	PTH
N	4	5	5	5
BV/TV (%)	11.9 ± 7.4	33.2 ± 8.6b	8.7 ± 1.2	39.2 ± 9.6b
Conn.D	244.6 ± 232.1	438.7 ± 165	132.2 ± 60.5	702.8 ± 168b
SMI	2.2 ± 0.9	0.1 ± 1.8	2.7 ± 0.2	−0.6 ± 1.0b
Tb.N (1/mm)	5.1 ± 2.1	8.3 ± 2.4b	4.8 ± 0.5	10.8 ± 1.3b
Tb.Th (mm)	0.04 ± 0.005	0.05 ± 0.009	0.034 ± 0.002a	0.051 ± 0.006b
Tb.Sp (mm)	0.2 ± 0.07	0.121 ± 0.05	0.2 ± 0.02	0.08 ± 0.02b
Ct.Ar (mm2)	0.43 ± 0.04	0.60 ± 0.05b	0.4 ± 0.03	0.5 ± 0.05b
Tt.Ar (mm2)	1.4 ± 0.1	1.6 ± 0.2	0.7 ± 0.09a	0.8 ± 0.1
Ct.Ar/Tt.Ar (%)	0.31 ± 0.01	0.38 ± 0.02b	0.57 ± 0.02a	0.63 ± 0.05
Ct.Th (mm)	0.1 ± 0.007	0.134 ± 0.004b	0.15 ± 0.015a	0.19 ± 0.01b
Ma.V (mm3)	1.16 ± 0.7	1.2 ± 0.2	0.42 ± 0.09a	0.37 ± 0.07
Imin (mm4)	0.06 ± 0.009	0.1 ± 0.02b	0.03 ± 0.006a	0.04 ± 0.01